Absci Corp
ABSI2.990USD
+0.090+3.10%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
381.35MMarket Cap
LossP/E TTM
More Details of Absci Corp Company
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
Company Info
Ticker SymbolABSI
Company nameAbsci Corp
IPO dateJul 22, 2021
CEOMr. Sean Mcclain
Number of employees156
Security typeOrdinary Share
Fiscal year-endJul 22
Address18105 Se Mill Plain Blvd
CityVANCOUVER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code98683
Phone13609491041
Websitehttps://www.absci.com/
Ticker SymbolABSI
IPO dateJul 22, 2021
CEOMr. Sean Mcclain
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Director
Director
--
--
Mr. Frans Van Houten
Mr. Frans Van Houten
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Joseph Sirosh, Ph.D.
Dr. Joseph Sirosh, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jun 24
Updated: Tue, Jun 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.08%
Investment Advisor/Hedge Fund
18.18%
Individual Investor
6.46%
Hedge Fund
4.02%
Corporation
3.29%
Research Firm
1.79%
Bank and Trust
0.24%
Venture Capital
0.21%
Pension Fund
0.02%
Other
29.72%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
307
100.37M
69.60%
-3.07M
2025Q1
316
100.15M
78.58%
-546.74K
2024Q4
298
92.04M
80.13%
-8.74M
2024Q3
280
90.06M
79.27%
-8.98M
2024Q2
257
91.26M
83.61%
+4.72M
2024Q1
236
84.09M
77.41%
+14.50M
2023Q4
202
58.01M
62.41%
-6.63M
2023Q3
196
57.87M
62.40%
-7.67M
2023Q2
191
58.28M
63.02%
-12.48M
2023Q1
181
65.82M
71.20%
-6.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
18.39M
14.41%
+4.87M
+36.07%
Mar 31, 2025
ARK Investment Management LLC
10.96M
8.59%
+2.69M
+32.53%
Mar 31, 2025
McClain (Sean)
8.73M
6.84%
+119.00K
+1.38%
Mar 31, 2025
Redmile Group, LLC
8.25M
6.47%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
4.69M
3.67%
-86.40K
-1.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.25M
4.9%
+325.67K
+5.50%
Mar 31, 2025
Phoenix Ventures Partners II LP.
4.75M
3.72%
-4.61M
-49.28%
Mar 31, 2025
Fred Alger Management, LLC
4.29M
3.37%
-2.21M
-33.99%
Mar 31, 2025
Columbia Wanger Asset Management, LLC
2.40M
1.88%
--
--
Mar 31, 2025
MFS Investment Management
2.31M
1.81%
+20.59K
+0.90%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
2.39%
WisdomTree BioRevolution Fund
0.95%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
View more
ARK Genomic Revolution ETF
Proportion2.39%
WisdomTree BioRevolution Fund
Proportion0.95%
iShares Micro-Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
